These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33883507)

  • 41. HeartWare and HeartMate II left ventricular assist devices as bridge to transplantation: a comparative analysis.
    Topkara VK; O'Neill JK; Carlisle A; Novak E; Silvestry SC; Ewald GA
    Ann Thorac Surg; 2014 Feb; 97(2):506-12. PubMed ID: 24140211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-Term Outcomes of Magnetically Levitated Left Ventricular Assist Device in Advanced Heart Failure　- The Japanese Cohort.
    Inoue K; Fujita T; Yoshioka D; Tonai K; Yanagino Y; Kakuta T; Tadokoro N; Kawamoto N; Yamashita K; Kawamura A; Matsuura R; Kawamura T; Saito T; Kawamura M; Kainuma S; Fukushima S; Toda K; Miyagawa S
    Circ J; 2022 Nov; 86(12):1961-1967. PubMed ID: 36273915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aortic Root Thrombosis in patients with HeartMate 3 left ventricular assist device support.
    Carey MR; Marshall D; Clerkin K; Laracuente R; Sanchez J; Jain SS; Raikhelkar JK; Leb JS; Kaku Y; Yuzefpolskaya M; Naka Y; Colombo PC; Sayer GT; Takeda K; Uriel N; Topkara VK; Fried JA
    J Heart Lung Transplant; 2024 Jun; 43(6):866-875. PubMed ID: 37739242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function.
    Lee S; Kamdar F; Madlon-Kay R; Boyle A; Colvin-Adams M; Pritzker M; John R
    J Heart Lung Transplant; 2010 Feb; 29(2):209-15. PubMed ID: 20113911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial.
    Goldstein DJ; Mehra MR; Naka Y; Salerno C; Uriel N; Dean D; Itoh A; Pagani FD; Skipper ER; Bhat G; Raval N; Bruckner BA; Estep JD; Cogswell R; Milano C; Fendelander L; O'Connell JB; Cleveland J;
    J Heart Lung Transplant; 2018 Jan; 37(1):7-14. PubMed ID: 29154131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions.
    Drakos SG; Stringham JC; Long JW; Gilbert EM; Fuller TC; Campbell BK; Horne BD; Hagan ME; Nelson KE; Lindblom JM; Meldrum PA; Carlson JF; Moore SA; Kfoury AG; Renlund DG
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1612-9. PubMed ID: 17532964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices.
    John R; Naka Y; Park SJ; Sai-Sudhakar C; Salerno C; Sundareswaran KS; Farrar DJ; Milano CA
    J Thorac Cardiovasc Surg; 2014 Feb; 147(2):581-9; discussion 589. PubMed ID: 24418362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant Cardiac Surgical Procedures in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation.
    Eisenberger J; Somer S; Nachum E; Ram E; Lavee J; Sternik L; Morgan J
    Isr Med Assoc J; 2024 May; 26(5):278-282. PubMed ID: 38736341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation.
    DeNofrio D; Rho R; Morales FJ; Kamoun M; Kearns J; Dorozinsky C; Rosengard BR; Acker MA; Loh E
    Transplantation; 2000 Mar; 69(5):814-8. PubMed ID: 10755532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of an improved driveline management for HeartMate II and HeartMate 3 left ventricular assist devices.
    Mutsuga M; Okumura T; Morimoto R; Kondo T; Ito H; Terazawa S; Tokuda Y; Narita Y; Nishida K; Murohara T; Usui A
    Artif Organs; 2023 Feb; 47(2):387-395. PubMed ID: 36269680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experience with the HeartMate II Left Ventricular Assist Device in Patients Older than 60 Years.
    Demirozu ZT; Critsinelis A; Cohn WE; Radovancevic R; Ho J; Hernandez R; Morgan JA; Frazier OH
    Heart Surg Forum; 2019 Mar; 22(2):E124-E130. PubMed ID: 31013222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential impact on post-transplant outcomes between pulsatile- and continuous-flow left ventricular assist devices.
    Ventura PA; Alharethi R; Budge D; Reid BB; Horne BD; Mason NO; Stoker S; Caine WT; Rasmusson B; Doty J; Clayson SE; Kfoury AG
    Clin Transplant; 2011; 25(4):E390-5. PubMed ID: 21401721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival.
    Pagani FD; Dyke DB; Wright S; Cody R; Aaronson KD
    J Heart Lung Transplant; 2001 Jun; 20(6):646-53. PubMed ID: 11404170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Mehra MR; Crandall DL; Gustafsson F; Jorde UP; Katz JN; Netuka I; Uriel N; Connors JM; Sood P; Heatley G; Pagani FD
    Eur J Heart Fail; 2021 Jul; 23(7):1226-1237. PubMed ID: 34142415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay.
    Shankar N; Daly R; Geske J; Kushwaha SK; Timmons M; Joyce L; Stulak J; Gandhi M; Kremers W; Park S; Pereira NL
    Transplantation; 2013 Aug; 96(3):324-30. PubMed ID: 23743727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The HeartMate 3 left ventricular assist device as a strategy to bridge to transplant.
    Kilcoyne MF; Huckaby LV; Hashmi Z; Witer L; Pope N; Houston BA; Inampudi C; Tedford RJ; Kilic A
    J Card Surg; 2022 Dec; 37(12):4713-4718. PubMed ID: 36321713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes.
    Alba AC; Tinckam K; Foroutan F; Nelson LM; Gustafsson F; Sander K; Bruunsgaard H; Chih S; Hayes H; Rao V; Delgado D; Ross HJ
    J Heart Lung Transplant; 2015 May; 34(5):685-92. PubMed ID: 25638296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.
    Ko BS; Drakos S; Kfoury AG; Hurst D; Stoddard GJ; Willis CA; Delgado JC; Hammond EH; Gilbert EM; Alharethi R; Revelo MP; Nativi-Nicolau J; Reid BB; McKellar SH; Wever-Pinzon O; Miller DV; Eckels DD; Fang JC; Selzman CH; Stehlik J;
    J Heart Lung Transplant; 2016 Aug; 35(8):1024-30. PubMed ID: 27316382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-year outcomes with the HeartMate 3 left ventricular assist device.
    Hanke JS; Dogan G; Zoch A; Ricklefs M; Wert L; Feldmann C; Bara C; Shrestha M; Tillmanns J; Kempf T; Bauersachs J; Haverich A; Schmitto JD
    J Thorac Cardiovasc Surg; 2018 Aug; 156(2):662-669. PubMed ID: 29525258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients.
    Marian U; Slavcev A; Gazdic T; Ivak P; Netuka I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Dec; 160(4):518-523. PubMed ID: 27132810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.